Alzheimer’s is responsible for 60% of the world’s estimated 50 million dementias. The heterogeneity of the disease makes Alzheimer’s diagnosis and counting the total number of affected people difficult. Every fifth patient has an atypical Alzheimer’s disease, which is often not recognized
This progressive neurodegenerative disease starts with microscopic changes in the brain long before the onset of the first symptoms. Currently there is no cure for this devastating condition. The disease is named after the german doctor Alois Alzheimer, who first described it in 1906 after he noticed characteristic changes in the brain of a deceased patient.
Aducanumab is an amyloid beta-directed monoclonal antibody. It targets aggregated forms of Amyloid beta (Aβ) found in the brains of people with Alzheimer’s disease to reduce its buildup.
Aducanumab is the first new treatment approved for Alzheimer’s since 2003. It was approved for medical use in the United States by the Food and Drug Administration (FDA) in June 2021, in a controversial decision due to ambiguous clinical trial results surrounding its efficacy.
Nevertheless, the drug was approved under the FDA’s accelerated approval pathway and the FDA requires follow-up studies to see if the drug helps treating symptoms of Alzheimer’s.
VelaLabs supports various clients in the development of disease modifying therapies
Our tailor-made assays cover product release for therapeutic drugs, measurement of amyloid oligomers and anti-amyloid beta antibodies in patient samples. With our services in analysing and characterization of biomolecules our experts are looking forward to answering your questions.
Contact us – we are looking forward to supporting your analysis needs
email@example.com I +43 189 059 7911.